Codiak BioSciences, Inc.
https://www.codiakbio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Codiak BioSciences, Inc.
Finance Watch: Have Investors Reached IPO Fatigue?
Public Company Edition: Codiak, Kiromic, Aligos and Opthea have fallen below their initial public offering values, while Tarsus and Praxis are trading higher. Also, 5AM, MPM and Cormorant took biotech SPACs public and Evotec led recent non-IPO financings with a €250m private placement.
Tech Transfer Roundup: Tonix Inks Trio Of COVID-19-Focused Deals
New York biotech is partnering with researchers at Columbia, Kansas State and Southern Research to address the pandemic.
Deal Watch: Merck Gets Rights To Yumanity’s Preclinical ALS, FTLD Candidates
Merck pays undisclosed upfront fees and promises up to $500m for milestones under licensing and collaboration agreement. Meanwhile, Tetraphase and Xerava are being acquired by La Jolla, after previous bids by Melinta and AcelRx.
ILIAS Biologics CEO On Opening Pandora’s Box For Exosome Therapeutics
Emerging Company Profile: South Korea-based ILIAS Biologics aims to establish an exosome therapeutic development pathway using its platform technology EXPLOR, which is said to enable loading large therapeutic proteins into exosomes and stably deliver encapsulated cargo proteins to target cells.
Company Information
- Industry
-
Pharmaceuticals
- Drug Delivery
- Vaccines
-
Biotechnology
- Antisense, Oligonucleotides
- Gene Therapy, Cell Therapy